Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

berberine; signaling pathways; oncogenic cascades; TRAIL; microRNAs; cancer therapy; colon cancer cells; ethanol; Nrf2; HO-1; ER stress; autophagy; MMPs; formononetin; cancer; preclinical models; cell signaling; angiogenesis; nobiletin; colorectal cancer; chemoprevention; bioactivities; experimental therapeutics; HDAC; multiple myeloma; oleacein; breast cancer; persistent organic pollutants; breast cancer risk; breast cancer prognostic; systematic review; carrageenan; invasion; metastasis; RacGAP1; radiotherapy; marine sponge; natural product; anticancer drug; oral cancer inhibition; phytochemicals; small organic agents; Piper eriopodon, alkenylphenols; human cancer cells; cell death; apoptosis; caspase-independent cell death; XIAP antagonists; XIAP-BIR3 domain; Calocedrus formosana; lung cancer; yatein; cell-cycle arrest; xenograft; isorhamnetin; G2/M arrest; ROS; AMPK; pancreatic cancer; epigallocatechin-3-gallate (EGCG); gemcitabine; glycolysis; phosphofructokinase; natural polyphenols; anticancer activities; molecular mechanisms; Streptomyces; mangrove; anti-proliferative; colon cancer; epithelial mesenchymal transition; inflammation; malignant cancer; natural anti-inflammatory compounds; pro-resolving lipids; anticancer drugs; flavonoids; natural compounds; Xenopus laevis; AOM/DSS model; melanoma cells; nicotine; α9-nAChR; PD-L1; STAT3; gigantol; AKT; JAK/STAT; cancer stem cell; tumor maintenance; tumor density; proteomics; honokiol; anticancer; mechanism; signalling pathway; uterine sarcoma; fucoidan; isobolography; colchicine alkaloid; mesoporous silica nanoparticles; targeted delivery system; PD-1 immune checkpoint inhibitor and cancer immunotherapy; glucose transport; drugs; innate immunity; β-glucans; nutrition; immunotherapy; estrogen; estrogen receptor alpha; polyphenols; daidzein; daidzein metabolites; paclitaxel; breast cancer cells; obesity; renin–angiotensin system; eicosapentaenoic acid; adipocyte inflammation; olive leaf extract; oleuropein; Seahorse analysis; cancer metabolism; glycolytic markers; Malva pseudolavatera Webb & Berthel.; acute myeloid leukemia; reactive oxygen species; brain cancer; gliomas; schwannomas; malignant tumors of the peripheral nerve sheath (MPNST); neurofibromas; bioavailability; nanoparticle-based delivery systems; natural bioactive compound; gallic acid; EGFR signaling; p53; EGCG; non-coding RNAs; anti-cancer drug; NSCLC; EGFR TKI; FASN inhibitors; resistance; n/a